Abstract
Glioblastoma is the most common primary malignant brain tumor and one of the most aggressive tumors across all cancer types with remarkable resistance to any treatment. While immunotherapy has shown a robust clinical benefit in systemic cancers, its benefit is still under investigation in brain cancers. The broader use of immunotherapy in clinical trials for glioblastoma has highlighted the challenges of traditional methods of monitoring progression via imaging. Development of new guidelines, advanced imaging techniques, and immune profiling have emerged to counter premature diagnoses of progressive disease. However, these approaches do not provide a timely diagnosis and are costly and time consuming. Surgery is currently the standard of care for diagnosis of pseudoprogression in cases where MRI is equivocal. However, it is invasive, risky, and disruptive to patient’s lives and their oncological treatment. With its increased vascularity, glioblastoma is continually shedding tumor components into the vasculature including tumor cells, genetic material, and extracellular vesicles. These elements can be isolated from routine blood draws and provide a real-time non-invasive indicator of tumor progression. Liquid biopsy therefore presents as an attractive alternative to current methods to guide treatment. While the initial evaluation of liquid biopsy for brain tumors via identification of mutations in the plasma was disappointing, novel technologies and use of alternatives to plasma cell-free DNA analytes provide promise for an effective liquid biopsy approach in brain tumors. This review aims to summarize developments in the use of liquid biopsy to monitor glioblastoma, especially in the context of immunotherapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Akers, J. C., Hua, W., Li, H., Ramakrishnan, V., Yang, Z., Quan, K., et al. (2017). A cerebrospinal fluid microRNA signature as biomarker for glioblastoma. Oncotarget, 8(40), 68769–68779. https://doi.org/10.18632/oncotarget.18332
Anagnostou, V., Forde, P. M., White, J. R., Niknafs, N., Hruban, C., Naidoo, J., et al. (2019). Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer. Cancer Research, 79(6), 1214–1225. https://doi.org/10.1158/0008-5472.CAN-18-1127
Artzi, M., Bokstein, F., Blumenthal, D. T., Aizenstein, O., Liberman, G., Corn, B. W., & Bashat, D. B. (2014). Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: A longitudinal MRI study. European Journal of Radiology, 83(7), 1250–1256.
Basler, L., Gabryś, H. S., Hogan, S. A., Pavic, M., Bogowicz, M., Vuong, D., et al. (2020). Radiomics, tumor volume, and blood biomarkers for early prediction of pseudoprogression in patients with metastatic melanoma treated with immune checkpoint inhibition. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-20-0020
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., et al. (2014). Detection of circulating tumor DNA in early- and late-stage human malignancies. Science Translational Medicine, 6(224), 224ra24. https://doi.org/10.1126/scitranslmed.3007094
Bratman, S. V., Yang, S. Y. C., Iafolla, M. A. J., Liu, Z., Hansen, A. R., Bedard, P. L., et al. (2020). Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nature Cancer, 1(9), 873–881. https://doi.org/10.1038/s43018-020-0096-5
Carthon, B. C., Wolchok, J. D., Yuan, J., Kamat, A., Ng Tang, D. S., Sun, J., et al. (2010). Preoperative CTLA-4 blockade: Tolerability and immune monitoring in the setting of a presurgical clinical trial. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 16(10), 2861–2871. https://doi.org/10.1158/1078-0432.CCR-10-0569
Chaddad, A., Sabri, S., Niazi, T., & Abdulkarim, B. (2018). Prediction of survival with multi-scale radiomic analysis in glioblastoma patients. Medical & Biological Engineering & Computing, 56(12), 2287–2300. https://doi.org/10.1007/s11517-018-1858-4
Chamberlain, M. C. (2008). Pseudoprogression in glioblastoma. Journal of Clinical Oncology, 26(26), 4359–4359. https://doi.org/10.1200/JCO.2008.18.4440
Chan, H. T., Chin, Y. M., Nakamura, Y., & Low, S.-K. (2020). Clonal hematopoiesis in liquid biopsy: From biological noise to valuable clinical implications. Cancers, 12(8), 2277. https://doi.org/10.3390/cancers12082277
Chistiakov, D. A., & Chekhonin, V. P. (2018). Circulating tumor cells and their advances to promote cancer metastasis and relapse, with focus on glioblastoma multiforme. Experimental and Molecular Pathology, 105(2), 166–174. https://doi.org/10.1016/j.yexmp.2018.07.007
Cloughesy, T. F., Mochizuki, A. Y., Orpilla, J. R., Hugo, W., Lee, A. H., Davidson, T. B., et al. (2019). Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nature Medicine, 25(3), 477–486. https://doi.org/10.1038/s41591-018-0337-7
Coppin, C., Porzsolt, F., Autenrieth, M., Kumpf, J., Coldman, A., & Wilt, T. (2004). Immunotherapy for advanced renal cell cancer. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD001425.pub2
Crane, C. A., Han, S. J., Ahn, B., Oehlke, J., Kivett, V., Fedoroff, A., et al. (2013). Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 19(1), 205–214. https://doi.org/10.1158/1078-0432.CCR-11-3358
Cristiano, S., Leal, A., Phallen, J., Fiksel, J., Adleff, V., Bruhm, D. C., et al. (2019). Genome-wide cell-free DNA fragmentation in patients with cancer. Nature, 570(7761), 385–389. https://doi.org/10.1038/s41586-019-1272-6
Crowley, E., Di Nicolantonio, F., Loupakis, F., & Bardelli, A. (2013). Liquid biopsy: Monitoring cancer-genetics in the blood. Nature Reviews Clinical Oncology, 10(8), 472–484. https://doi.org/10.1038/nrclinonc.2013.110
Davis, M. E. (2016). Glioblastoma: Overview of disease and treatment. Clinical Journal of Oncology Nursing, 20(5), S2–S8. https://doi.org/10.1188/16.CJON.S1.2-8
Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., et al. (2013). Analysis of circulating tumor DNA to monitor metastatic breast cancer. The New England Journal of Medicine, 368(13), 1199–1209. https://doi.org/10.1056/NEJMoa1213261
Delgado-López, P. D., & Corrales-García, E. M. (2016). Survival in glioblastoma: A review on the impact of treatment modalities. Clinical and Translational Oncology, 18(11), 1062–1071. https://doi.org/10.1007/s12094-016-1497-x
Desjardins, A., Gromeier, M., Herndon, J. E., Beaubier, N., Bolognesi, D. P., Friedman, A. H., et al. (2018). Recurrent glioblastoma treated with recombinant poliovirus. New England Journal of Medicine, 379(2), 150–161. https://doi.org/10.1056/NEJMoa1716435
Di Meo, A., Bartlett, J., Cheng, Y., Pasic, M. D., & Yousef, G. M. (2017). Liquid biopsy: A step forward towards precision medicine in urologic malignancies. Molecular Cancer, 16(1), 80. https://doi.org/10.1186/s12943-017-0644-5
Diaz, L. A., & Bardelli, A. (2014). Liquid biopsies: Genotyping circulating tumor DNA. Journal of Clinical Oncology, 32(6), 579–586. https://doi.org/10.1200/JCO.2012.45.2011
Diehl, F., Schmidt, K., Choti, M. A., Romans, K., Goodman, S., Li, M., et al. (2008). Circulating mutant DNA to assess tumor dynamics. Nature Medicine, 14(9), 985–990. https://doi.org/10.1038/nm.1789
Elshafeey, N., Kotrotsou, A., Hassan, A., Elshafei, N., Hassan, I., Ahmed, S., et al. (2019). Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma. Nature Communications, 10(1), 1–9.
Everaert, C., Helsmoortel, H., Decock, A., Hulstaert, E., Van Paemel, R., Verniers, K., et al. (2019). Performance assessment of total RNA sequencing of human biofluids and extracellular vesicles. Scientific Reports, 9(1), 17574. https://doi.org/10.1038/s41598-019-53892-x
Farina, M. S., Lundgren, K. T., & Bellmunt, J. (2017). Immunotherapy in urothelial cancer: Recent results and future perspectives. Drugs, 77(10), 1077–1089. https://doi.org/10.1007/s40265-017-0748-7
Frelaut, M., du Rusquec, P., de Moura, A., Le Tourneau, C., & Borcoman, E. (2020). Pseudoprogression and hyperprogression as new forms of response to immunotherapy. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy, 34, 463–476.
Gao, F., Cui, Y., Jiang, H., Sui, D., Wang, Y., Jiang, Z., et al. (2016). Circulating tumor cell is a common property of brain glioma and promotes the monitoring system. Oncotarget, 7(44), 71330–71340. https://doi.org/10.18632/oncotarget.11114
Gao, X., Zhang, M., Tang, Y., & Liang, X. (2017). Cancer cell dormancy: Mechanisms and implications of cancer recurrence and metastasis. Oncotargets and Therapy. https://doi.org/10.2147/OTT.S140854
Gevaert, O., Mitchell, L. A., Achrol, A. S., Xu, J., Echegaray, S., Steinberg, G. K., et al. (2014). Glioblastoma multiforme: Exploratory radiogenomic analysis by using quantitative image features. Radiology, 273(1), 168–174.
Gubin, M. M., Esaulova, E., Ward, J. P., Malkova, O. N., Runci, D., Wong, P., et al. (2018). High-dimensional analysis delineates myeloid and lymphoid compartment remodeling during successful immune-checkpoint cancer therapy. Cell, 175(4), 1014-1030.e19. https://doi.org/10.1016/j.cell.2018.09.030
Han, L., Lam, E.W.-F., & Sun, Y. (2019). Extracellular vesicles in the tumor microenvironment: Old stories, but new tales. Molecular Cancer, 18(1), 59. https://doi.org/10.1186/s12943-019-0980-8
Hanif, F., Muzaffar, K., Perveen, K., Malhi, S. M., & Simjee, S. U. (2017). Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pacific Journal of Cancer Prevention: APJCP, 18(1), 3–9. https://doi.org/10.22034/APJCP.2017.18.1.3
Heitzer, E., Ulz, P., & Geigl, J. B. (2015). Circulating tumor DNA as a liquid biopsy for cancer. Clinical Chemistry, 61(1), 112–123. https://doi.org/10.1373/clinchem.2014.222679
Huang, K., Fang, C., Yi, K., Liu, X., Qi, H., Tan, Y., et al. (2018). The role of PTRF/Cavin1 as a biomarker in both glioma and serum exosomes. Theranostics, 8(6), 1540–1557. https://doi.org/10.7150/thno.22952
Jackson, C. M., Choi, J., & Lim, M. (2019). Mechanisms of immunotherapy resistance: Lessons from glioblastoma. Nature Immunology, 20(9), 1100–1109. https://doi.org/10.1038/s41590-019-0433-y
Jamshidi, N., Diehn, M., Bredel, M., & Kuo, M. D. (2014). Illuminating radiogenomic characteristics of glioblastoma multiforme through integration of MR imaging, messenger RNA expression, and DNA copy number variation. Radiology, 270(1), 1–2. https://doi.org/10.1148/radiol.13130078
Jiang, P., Chan, C. W. M., Chan, K. C. A., Cheng, S. H., Wong, J., Wong, V.W.-S., et al. (2015). Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proceedings of the National Academy of Sciences of the United States of America, 112(11), E1317-1325. https://doi.org/10.1073/pnas.1500076112
Kasten, B. B., Udayakumar, N., Leavenworth, J. W., Wu, A. M., Lapi, S. E., McConathy, J. E., et al. (2019). Current and future imaging methods for evaluating response to immunotherapy in neuro-oncology. Theranostics, 9(17), 5085–5104. https://doi.org/10.7150/thno.34415
Korpics, M. C., Bhave, S. R., Redler, G., Pitroda, S., Luke, J. J., & Chmura, S. J. (2019). A validated radiomics T-cell score predicts response to multi-site SBRT combined with pembrolizumab. International Journal of Radiation Oncology Biology Physics, 105(1), S74.
Kumar, V., Gu, Y., Basu, S., Berglund, A., Eschrich, S. A., Schabath, M. B., et al. (2012). Radiomics: The process and the challenges. Magnetic Resonance Imaging, 30(9), 1234–1248.
Lan, F., Yue, X., & Xia, T. (2020). Exosomal microRNA-210 is a potentially non-invasive biomarker for the diagnosis and prognosis of glioma. Oncology Letters, 19(3), 1967–1974. https://doi.org/10.3892/ol.2020.11249
Lee, J. H., Long, G. V., Menzies, A. M., Lo, S., Guminski, A., Whitbourne, K., et al. (2018). Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. JAMA Oncology, 4(5), 717. https://doi.org/10.1001/jamaoncol.2017.5332
Lee, J., Narang, S., Martinez, J., Rao, G., & Rao, A. (2015). Spatial habitat features derived from multiparametric magnetic resonance imaging data are associated with molecular subtype and 12-month survival status in glioblastoma multiforme. PLoS ONE, 10(9), e0136557.
Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018). Current state of immunotherapy for glioblastoma. Nature Reviews Clinical Oncology, 15(7), 422–442. https://doi.org/10.1038/s41571-018-0003-5
Limkin, E. J., & Sun, R. (2020). Radiomics to predict response to immunotherapy: An imminent reality? Future Oncology. https://doi.org/10.2217/fon-2020-0015
Luke, J. J., Flaherty, K. T., Ribas, A., & Long, G. V. (2017). Targeted agents and immunotherapies: Optimizing outcomes in melanoma. Nature Reviews Clinical Oncology, 14(8), 463–482. https://doi.org/10.1038/nrclinonc.2017.43
Luksik, A. S., Maxwell, R., Garzon-Muvdi, T., & Lim, M. (2017). The role of immune checkpoint inhibition in the treatment of brain tumors. Neurotherapeutics, 14(4), 1049–1065. https://doi.org/10.1007/s13311-017-0513-3
Lun, M., Lok, E., Gautam, S., Wu, E., & Wong, E. T. (2011). The natural history of extracranial metastasis from glioblastoma multiforme. Journal of Neuro-Oncology, 105(2), 261–273. https://doi.org/10.1007/s11060-011-0575-8
MacArthur, K. M., Kao, G. D., Chandrasekaran, S., Alonso-Basanta, M., Chapman, C., Lustig, R. A., et al. (2014). Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay. Cancer Research, 74(8), 2152–2159. https://doi.org/10.1158/0008-5472.CAN-13-0813
Mair, R., Mouliere, F., Smith, C. G., Chandrananda, D., Gale, D., Marass, F., et al. (2019). Measurement of plasma cell-free mitochondrial tumor DNA improves detection of glioblastoma in patient-derived orthotopic xenograft models. Cancer Research, 79(1), 220–230. https://doi.org/10.1158/0008-5472.CAN-18-0074
Markovic, S. N., Galli, F., Suman, V. J., Nevala, W. K., Paulsen, A. M., Hung, J. C., et al. (2018). Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: A pilot study. Oncotarget, 9(54), 30268–30278. https://doi.org/10.18632/oncotarget.25666
Mathai, R. A., Vidya, R. V. S., Reddy, B. S., Thomas, L., Udupa, K., Kolesar, J., & Rao, M. (2019). Potential utility of liquid biopsy as a diagnostic and prognostic tool for the assessment of solid tumors: Implications in the precision oncology. Journal of Clinical Medicine, 8(3), 373. https://doi.org/10.3390/jcm8030373
Medikonda, R., Dunn, G., Rahman, M., Fecci, P., & Lim, M. (2020). A review of glioblastoma immunotherapy. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-020-03448-1
Mieghem, E. V., Wozniak, A., Geussens, Y., Menten, J., Vleeschouwer, S. D., Calenbergh, F. V., et al. (2013). Defining pseudoprogression in glioblastoma multiforme. European Journal of Neurology, 20(10), 1335–1341. https://doi.org/10.1111/ene.12192
Miller, A. M., Shah, R. H., Pentsova, E. I., Pourmaleki, M., Briggs, S., Distefano, N., et al. (2019). Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature, 565(7741), 654–658. https://doi.org/10.1038/s41586-019-0882-3
Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., et al. (2020). Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. Nature Cancer, 1(2), 176–183. https://doi.org/10.1038/s43018-019-0011-0
Moldenhauer, G., Momburg, F., Möller, P., Schwartz, R., & Hämmerling, G. J. (1987). Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker. British Journal of Cancer, 56(6), 714–721.
Mouliere, F., Chandrananda, D., Piskorz, A. M., Moore, E. K., Morris, J., Ahlborn, L. B., et al. (2018a). Enhanced detection of circulating tumor DNA by fragment size analysis. Science Translational Medicine, 10(466), 4921. https://doi.org/10.1126/scitranslmed.aat4921
Mouliere, F., Mair, R., Chandrananda, D., Marass, F., Smith, C. G., Su, J., et al. (2018b). Detection of cell-free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients. EMBO Molecular Medicine, 10(12), e9323. https://doi.org/10.15252/emmm.201809323
Müller, C., Holtschmidt, J., Auer, M., Heitzer, E., Lamszus, K., Schulte, A., et al. (2014). Hematogenous dissemination of glioblastoma multiforme. Science Translational Medicine, 6(247), 247ra101. https://doi.org/10.1126/scitranslmed.3009095
Nabavizadeh, S. A., Ware, J. B., Guiry, S., Nasrallah, M. P., Mays, J. J., Till, J. E., et al. (2020). Imaging and histopathologic correlates of plasma cell-free DNA concentration and circulating tumor DNA in adult patients with newly diagnosed glioblastoma. Neuro-Oncology Advances, 2(1), 16. https://doi.org/10.1093/noajnl/vdaa016
Nassiri, F., Chakravarthy, A., Feng, S., Shen, S. Y., Nejad, R., Zuccato, J. A., et al. (2020). Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes. Nature Medicine, 26(7), 1044–1047. https://doi.org/10.1038/s41591-020-0932-2
Nelson, B. (2009). Empty archives: Most researchers agree that open access to data is the scientific ideal, so what is stopping it happening? Bryn Nelson investigates why many researchers choose not to share. Nature, 461(7261), 160–164.
Nicholas, S., Mathios, D., Ruzevick, J., Jackson, C., Yang, I., & Lim, M. (2013). Current trends in glioblastoma multiforme treatment: Radiation therapy and immune checkpoint inhibitors. Brain Tumor Research and Treatment, 1(1), 2–8. https://doi.org/10.14791/btrt.2013.1.1.2
Okada, H., Weller, M., Huang, R., Finocchiaro, G., Gilbert, M. R., Wick, W., et al. (2015). Immunotherapy Response Assessment in Neuro-Oncology (iRANO): A report of the RANO Working Group. The Lancet Oncology, 16(15), e534–e542. https://doi.org/10.1016/S1470-2045(15)00088-1
Pantel, K., & Alix-Panabières, C. (2013). Real-time liquid biopsy in cancer patients: Fact or fiction? Cancer Research, 73(21), 6384–6388. https://doi.org/10.1158/0008-5472.CAN-13-2030
Pantel, K., & Alix-Panabières, C. (2019). Liquid biopsy and minimal residual disease—latest advances and implications for cure. Nature Reviews Clinical Oncology, 16(7), 409–424. https://doi.org/10.1038/s41571-019-0187-3
Piccioni, D. E., Achrol, A. S., Kiedrowski, L. A., Banks, K. C., Boucher, N., Barkhoudarian, G., et al. (2019). Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors. CNS Oncology, 8(2), CNS34. https://doi.org/10.2217/cns-2018-0015
Preusser, M., Lim, M., Hafler, D. A., Reardon, D. A., & Sampson, J. H. (2015). Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nature Reviews Neurology, 11(9), 504–514. https://doi.org/10.1038/nrneurol.2015.139
Raposo, G., & Stoorvogel, W. (2013). Extracellular vesicles: Exosomes, microvesicles, and friends. Journal of Cell Biology, 200(4), 373–383. https://doi.org/10.1083/jcb.201211138
Reardon, D. A., Brandes, A. A., Omuro, A., Mulholland, P., Lim, M., Wick, A., et al. (2020). Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: The CheckMate 143 phase 3 randomized clinical trial. JAMA Oncology, 6(7), 1003–1010. https://doi.org/10.1001/jamaoncol.2020.1024
Sampson, J. H., Heimberger, A. B., Archer, G. E., Aldape, K. D., Friedman, A. H., Friedman, H. S., et al. (2010). Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28(31), 4722–4729. https://doi.org/10.1200/JCO.2010.28.6963
Santangelo, A., Imbrucè, P., Gardenghi, B., Belli, L., Agushi, R., Tamanini, A., et al. (2018). A microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker. Journal of Neuro-Oncology, 136(1), 51–62. https://doi.org/10.1007/s11060-017-2639-x
Schumacher, T., Bunse, L., Pusch, S., Sahm, F., Wiestler, B., Quandt, J., et al. (2014). A vaccine targeting mutant IDH1 induces antitumour immunity. Nature, 512(7514), 324–327. https://doi.org/10.1038/nature13387
Selby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013). Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunology Research, 1(1), 32–42. https://doi.org/10.1158/2326-6066.CIR-13-0013
Sherriff, J., Tamangani, J., Senthil, L., Cruickshank, G., Spooner, D., Jones, B., et al. (2013). Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide. The British Journal of Radiology, 86(1022), 20120414. https://doi.org/10.1259/bjr.20120414
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., et al. (2013). Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. The Journal of Experimental Medicine, 210(9), 1695–1710. https://doi.org/10.1084/jem.20130579
Soeda, A., Hara, A., Kunisada, T., Yoshimura, S., Iwama, T., & Park, D. M. (2015). The evidence of glioblastoma heterogeneity. Scientific Reports, 5(1), 7979. https://doi.org/10.1038/srep07979
Sullivan, J. P., Nahed, B. V., Madden, M. W., Oliveira, S. M., Springer, S., Bhere, D., et al. (2014). Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discovery, 4(11), 1299–1309. https://doi.org/10.1158/2159-8290.CD-14-0471
Sun, R., Limkin, E. J., Vakalopoulou, M., Dercle, L., Champiat, S., Han, S. R., et al. (2018). A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: An imaging biomarker, retrospective multicohort study. The Lancet Oncology, 19(9), 1180–1191.
Trebeschi, S., Drago, S. G., Birkbak, N. J., Kurilova, I., Cǎlin, A. M., Delli Pizzi, A., et al. (2019). Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. Annals of Oncology, 30(6), 998–1004.
Umetani, N., Giuliano, A. E., Hiramatsu, S. H., Amersi, F., Nakagawa, T., Martino, S., & Hoon, D. S. B. (2006). Prediction of breast tumor progression by integrity of free circulating DNA in serum. Journal of Clinical Oncology, 24(26), 4270–4276. https://doi.org/10.1200/JCO.2006.05.9493
Vansteenkiste, J., Zielinski, M., Linder, A., Dahabreh, J., Gonzalez, E. E., Malinowski, W., et al. (2013). Adjuvant MAGE-A3 immunotherapy in resected non–small-cell lung cancer: Phase II randomized study results. Journal of Clinical Oncology, 31(19), 2396–2403. https://doi.org/10.1200/JCO.2012.43.7103
Wang, Y., Zhou, Y., & Hu, Z. (2017). The functions of circulating tumor cells in early diagnosis and surveillance during cancer advancement. Journal of Translational Internal Medicine, 5(3), 135–138. https://doi.org/10.1515/jtim-2017-0029
Wang, Y., Springer, S., Zhang, M., McMahon, K. W., Kinde, I., Dobbyn, L., et al. (2015). Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proceedings of the National Academy of Sciences of the United States of America, 112(31), 9704–9709. https://doi.org/10.1073/pnas.1511694112
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., et al. (2010). Updated response assessment criteria for high-grade gliomas: Response assessment in Neuro-Oncology Working Group. Journal of Clinical Oncology, 28(11), 1963–1972. https://doi.org/10.1200/JCO.2009.26.3541
Wolchok, J. D., Hoos, A., O’Day, S., Weber, J. S., Hamid, O., Lebbé, C., et al. (2009). Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clinical Cancer Research, 15(23), 7412–7420. https://doi.org/10.1158/1078-0432.CCR-09-1624
Zhang, W., Xia, W., Lv, Z., Xin, Y., Ni, C., & Yang, L. (2017). Liquid biopsy for cancer: Circulating tumor cells, circulating free DNA or exosomes? Cellular Physiology and Biochemistry, 41(2), 755–768. https://doi.org/10.1159/000458736
Zhang, Y., Mudgal, P., Wang, L., Wu, H., Huang, N., Alexander, P. B., et al. (2020). T cell receptor repertoire as a prognosis marker for heat shock protein peptide complex-96 vaccine trial against newly diagnosed glioblastoma. Oncoimmunology, 9(1), 1749476. https://doi.org/10.1080/2162402X.2020.1749476
Zviran, A., Schulman, R. C., Shah, M., Hill, S. T. K., Deochand, S., Khamnei, C. C., et al. (2020). Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nature Medicine, 26(7), 1114–1124. https://doi.org/10.1038/s41591-020-0915-3
Author information
Authors and Affiliations
Contributions
Conceptualization: DM, CB, ML; literature search and data analysis: DM, SS, and TK. The first draft of the manuscript was written by DM, SS, and TK. All authors commented, critically revised, and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Mathios, D., Srivastava, S., Kim, T. et al. Emerging Technologies for Non-invasive Monitoring of Treatment Response to Immunotherapy for Brain Tumors. Neuromol Med 24, 74–87 (2022). https://doi.org/10.1007/s12017-021-08677-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12017-021-08677-9